Company profile
Avenue Therapeutics, Inc.
OTC: ATXI · Healthcare · Biotechnology
#843 of 1,422 Healthcare companies by revenue
EA Score
25DFH 33DQ 12GM —SS 26
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, listing tenure · ↓ workforce scale, disclosure history
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$2.9M
Employees
1
as of 2026-08-26
Market cap
$1.3M
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.4M$1.4M2025
Net income-$2.9M-$2.9M2025
Operating income-$3.1M-$3.1M2025
Total assets$2.9M$2.9M2025
Liabilities$1.1M$1.1M2025
Equity$1.8M$1.8M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Avenue Therapeutics, Inc.’s revenue?
Avenue Therapeutics, Inc. booked $1.4M in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -207.2% net margin.
Peers · Healthcare
Perspective Therapeutics, Inc.46DBraxia Scientific Corp.——Outlook Therapeutics, Inc.22DWinston Pharmaceuticals, Inc.——Vasamed, Inc.——Northwest Biotherapeutics, Inc.40DNeighbors
New York →Key facts
CEOAlexandra MacLean
SectorHealthcare
IndustryBiotechnology
HeadquartersNew York City, NY
ExchangeOTC: ATXI
Employees1
IPO date2017-06-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.